Latest news with #MazeTherapeutics
Associated Press
29-05-2025
- Business
- Associated Press
Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present a company overview at the Jefferies 2025 Global Healthcare Conference on Thursday, June 5, 2025 at 2 p.m. ET. A live webcast will be available in the Investors section of the company's website at and archived for 60 days following the presentation. About Maze Therapeutics Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. The company is advancing a pipeline using its Compass platform, which provides insights into the genetic variants in disease and links them with the biological pathways that drive disease in specific patient groups. The company's pipeline is led by two wholly owned programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for patients. For more information, please visit or follow the company on LinkedIn and X. IR/Corporate Contact: Amy Bachrodt, Maze Therapeutics [email protected] Media Contact: Dan Budwick, 1AB [email protected]
Yahoo
29-05-2025
- Business
- Yahoo
Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present a company overview at the Jefferies 2025 Global Healthcare Conference on Thursday, June 5, 2025 at 2 p.m. ET. A live webcast will be available in the Investors section of the company's website at and archived for 60 days following the presentation. About Maze TherapeuticsMaze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. The company is advancing a pipeline using its Compass platform, which provides insights into the genetic variants in disease and links them with the biological pathways that drive disease in specific patient groups. The company's pipeline is led by two wholly owned programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for patients. For more information, please visit or follow the company on LinkedIn and X. IR/Corporate Contact:Amy Bachrodt, Maze Therapeuticsabachrodt@ Media Contact:Dan Budwick, 1ABdan@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
15-05-2025
- Business
- Business Insider
Maze Therapeutics, Inc. (MAZE) Gets a Buy from TD Cowen
In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Maze Therapeutics, Inc. (MAZE – Research Report). The company's shares closed today at $9.06. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Van Buren is an analyst with an average return of -5.2% and a 36.16% success rate. Van Buren covers the Healthcare sector, focusing on stocks such as BridgeBio Pharma, Regeneron, and Travere Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Maze Therapeutics, Inc. with a $25.67 average price target.
Yahoo
22-02-2025
- Health
- Yahoo
This New Drug Mimics The Health Effects of Living at High Altitude
Scientists are designing a new type of drug that mimics the physiological benefits of breathing in thin 'mountain air'. Continuous low-oxygen provided by a daily pill could prove life-saving for people with serious metabolic diseases, like Leigh syndrome. The new medicine, called HypoxyStat, extended the lifespan of mice with too much oxygen in their brains by up to 4-fold, reports a US team from Gladstone Institutes, the University of California San Francisco, and the pharmaceutical company Maze Therapeutics. In their proof-of-concept experiment, the drug worked even when given to mice in a late stage of neurodegeneration, where brain lesions are extensive and some animals are on the brink of death. The advanced damage was reversed, and movement, muscle weakness, and loss of coordination were improved. Leigh syndrome is a rare, progressive disease where mitochondria can't use the body's oxygen fast enough. Oxygen buildup in tissues can lead to damage and ultimately cell death. Children with Leigh syndrome often die within the first few years of life. Only about 20 percent make it to age 20. Typically, all but 2 percent of inhaled oxygen ends up in the body's mitochondria – famously known as the 'powerhouse' of the cell because of its ability to use oxygen for energy production. But in high-altitude regions, the body shifts so that oxygen is not as easily delivered from the bloodstream to tissues. In a groundbreaking 2016 experiment, researchers found that for mouse models of Leigh syndrome, living in a low-oxygen environment not only prevents brain damage; it also reverses it. Further studies on mice in 2017 and 2019 confirmed those remarkable results. It's not clear if humans with Leigh syndrome respond in the same way to low-oxygen environments. But biochemist Isha Jain from the University of California San Francisco (UCSF) and her colleagues are already exploring a way to mimic those effects pharmaceutically. Unlike sleeping in a hypobaric chamber, as some athletes do when training for high-altitude events, a drug that tricks the body into functioning like it would high up in the mountains could work virtually all day, leaving a person free to go about their usual business, inside or outside. "It's not practical for every patient with this disease to move to the mountains," says Jain, an author on all three of the papers as well as the current study. "But this drug could be a controlled and safe way to apply the same benefits to patients." Jain was previously a consultant for Maze Therapeutics, who sponsored this HypoxyStat study, and she has patents related to hypoxia therapy. She and her colleagues hypothesized that by making red blood cells carry more oxygen in the bloodstream, as they do in high-altitude environments, the amount of oxygen offloaded into the body's tissues would be reduced. In 2017, researchers found a drug, called GBT-440 or Voxelotor, that increases the affinity of the red cell protein hemoglobin to bind oxygen. When Jain and her team, led by biochemist Skyler Blume, incubated human red blood cells with GBT-440, they noticed the cells increased their affinity for hemoglobin by 75 percent. Emboldened by their results, the researchers found another compound like GBT-440 and named it HypoxyStat. Mice with Leigh syndrome that were treated with HypoxyStat showed a significant reduction in brain damage, shown by the green markers of lesions in the image below. Even in later stages of the disease, a daily dose of this drug greatly extended mouse lifespans and reversed extensive damage in the brain. "This ability to reverse advanced pathology positions HypoxyStat and related compounds as promising therapeutic candidates for mitochondrial diseases, where early diagnosis and intervention are often challenging," the authors of the study conclude. The research team is now exploring a second-generation version of HypoxyStat that could better translate to primate models or human clinical trials. "Gas-based therapies for disease are really unique, and being able to bottle them up into drugs is a new, unusual concept," says Jain. "We're excited to see where this promising strategy takes us." The study was published in Cell. The Seeds of Schizophrenia May Be Planted in The Earliest Moments of Life Ozempic Literally Came From a Monster – And It's Not Alone Sexual Competition May Actually Boost Men's Semen Quality
Reuters
31-01-2025
- Business
- Reuters
Maze Therapeutics valued at $690.4 million as shares rise marginally in market debut
Jan 31 (Reuters) - Shares of Maze Therapeutics (MAZE.O), opens new tab rose nearly 1% in their Nasdaq debut on Friday, valuing the kidney disease drug developer at $690.37 million. The company's shares opened at $16.12 apiece, compared with the IPO price of $16. San Francisco, California-based Maze upsized its IPO to sell 8.75 million shares within the marketed range of $15 to $17 each to raise $140 million. The company had initially planned to offer 7.8 million shares. The market reaction signals sustained investor appetite for IPOs, despite muted first-day performances from some high-profile firms such as Venture Global (VG.N), opens new tab and Smithfield Foods (SFD.O), opens new tab in the last few days. Maze's debut could be a positive signal for other biotech players looking to test investor interest in 2025. Drug developers Aardvark Therapeutics, Aurion Biotech, Sionna Therapeutics and Odyssey Therapeutics are among the IPO hopefuls that have filed their paperwork in recent weeks. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
